https://www.businesswire.com/news/home/20231011383566/en/EpimAb-Biotherapeutics-and-Almirall-Announce-Bispecific-Antibody-License-Agreement
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement
EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies, and Almirall, a global biopha...
biotherapeuticsalmirallannouncebispecificantibody